聚乙烯甘洛克森化物通过降低系统性炎症和改善内皮原生细胞功能来加速糖尿病伤口愈合
Zerui Ding1, Chunru Yang1, Xiaojun Zhai1
1Key Laboratory of Endocrinology National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
International journal of molecular sciences
|March 13, 2025
概括
聚乙烯甘醇色胺 (PEG-loxe),一种GLP-1RA,通过改善葡萄糖代谢,减少炎症和增强血管形成,加速糖尿病伤口愈合. 这项研究表明,PEG-loxe对内皮原生细胞有好处,这表明它有治疗糖尿病并发症的潜力.
科学领域:
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
- 伤口治愈研究研究 伤口治愈研究
背景情况:
- 由于葡萄糖代谢受损和血管功能障碍,糖尿病伤口愈合具有挑战性.
- 像PEG-loxe这样的长效葡萄糖类-1受体激动剂 (GLP-1RAs) 对心血管有好处,但它们对糖尿病伤口愈合的影响尚不清楚.
研究的目的:
- 研究PEG-loxe在糖尿病伤口愈合中的治疗潜力.
- 阐明PEG-loxe对葡萄糖代谢,血管生成和糖尿病炎症的影响背后的机制.
主要方法:
- 糖尿病小鼠接受了PEG-loxe治疗;评估了葡萄糖代谢,伤口关闭和血管生成.
- 血清蛋白质组学确定了炎症标记物的变化.
- 在人体内皮质原生细胞 (EPC) 的体外研究检查了PEG-loxe对细胞功能,线粒体活性和自的作用.
主要成果:
- 在糖尿病小鼠中,PEG-loxe改善了葡萄糖耐受性和加速了伤口关闭.
- 治疗提高了HIF-1α/VEGF/SDF-1轴的调节,并减少了全身炎症.
- 在体外,PEG-loxe增强了EPC功能,氧化生产,细胞呼吸和自,同时降低了线粒体ROS.
结论:
- PEG-loxe证明了糖尿病伤口愈合的治疗益处.
- 机制包括减少系统性炎症,增强血管生成,改善EPC线粒体质量控制.
- GLP-1RAs代表了糖尿病血管并发症的有希望的治疗策略.
相关概念视频
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:23Peripheral Artery Disease V: Postoperative Nursing Management
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
01:31Diabetic Foot Ulcer
Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...